Crescent Biopharma, Inc.(CBIO)
Biotechnology
Antibody Engineering (mAbs, bispecifics, ADCs)
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-12-08 | Harwin Peter Evan Director, 10% Owner | Purchase | +1,491,434 | +49.31%4,516,006 | $13.41 | $19,999,999 | View SEC filing | |
| 2024-08-09 | DEBBANE RAYMOND 10% Owner | Sale | -322,361 | -4.85%6,317,565 | $0.19 | $61,206 | View SEC filing | |
| 2024-08-07 | DEBBANE RAYMOND 10% Owner | Sale | -220,255 | -3.21%6,639,926 | $0.19 | $41,184 | View SEC filing | |
| 2024-08-05 | DEBBANE RAYMOND 10% Owner | Sale | -349,764 | -4.85%6,860,181 | $0.20 | $71,097 | View SEC filing | |
| 2024-07-30 | DEBBANE RAYMOND 10% Owner | Sale | -1,379,119 | -16.06%7,209,945 | $0.23 | $315,262 | View SEC filing | |
| 2024-06-24 | Rock Edwin Chief Medical Officer | Purchase | +305,000 | +81.25%680,403 | $0.26 | $78,825 | View SEC filing | |
| 2024-06-20 | Hahn Brian M. SVP Finance, CFO | Purchase | +17,500 | +32.93%70,643 | $0.25 | $4,335 | View SEC filing | |
| 2023-09-25 | Rock Edwin Chief Medical Officer | Purchase | +65,403 | +21.10%375,403 | $1.38 | $90,256 | View SEC filing | |
| 2023-05-18 | Hahn Brian M. SVP Finance, CFO | Sale | -3,700 | -6.51%53,143 | $1.95 | $7,215 | View SEC filing | |
| 2023-05-11 | JUNIUS DANIEL M Director | Purchase | +30,000 | +47.43%93,250 | $1.56 | $46,800 | View SEC filing | |
| 2023-05-09 | Johnson Bruce S SVP & Chief Commercial Officer | Purchase | +13,500 | +10.76%138,980 | $1.57 | $21,195 | View SEC filing | |
| 2023-02-28 | Artal Group S.A. 10% Owner | Purchase | +100,000 | +1.18%8,589,064 | $1.70 | $170,000 | View SEC filing | |
| 2023-02-23 | Artal Group S.A. 10% Owner | Purchase | +400,000 | +4.94%8,489,064 | $1.78 | $712,255 | View SEC filing | |
| 2023-02-17 | Artal Group S.A. 10% Owner | Purchase | +1,515,266 | +23.05%8,089,064 | $2.00 | $3,027,929 | View SEC filing | |
| 2023-02-13 | Artal Group S.A. 10% Owner | Purchase | +11,451 | +0.17%6,573,798 | $3.24 | $37,123 | View SEC filing | |
| 2023-01-27 | SANDELL SCOTT D 10% Owner | Sale | -3,652,016 | -42.37%4,967,530 | $3.14 | $11,484,515 | View SEC filing | |
| 2023-01-06 | SANDELL SCOTT D 10% Owner | Sale | -71,362 | -0.82%8,619,546 | $2.76 | $196,859 | View SEC filing | |
| 2023-01-04 | SANDELL SCOTT D 10% Owner | Sale | -398,133 | -4.38%8,690,908 | $2.98 | $1,185,886 | View SEC filing | |
| 2022-12-27 | Rock Edwin Chief Medical Officer | Purchase | +110,000 | +55.00%310,000 | $2.25 | $247,500 | View SEC filing | |
| 2022-11-18 | JUNIUS DANIEL M Director | Purchase | +20,000 | +46.24%63,250 | $1.87 | $37,400 | View SEC filing | |
| 2022-11-16 | Rock Edwin Chief Medical Officer | Purchase | +200,000 | +100.00%200,000 | $1.54 | $309,000 | View SEC filing | |
| 2022-11-14 | PEARSON TIMOTHY R Director | Purchase | +19,400 | +369.52%24,650 | $1.29 | $25,026 | View SEC filing | |
| 2022-11-14 | Semerjian Harout Chief Executive Officer | Purchase | +25,000 | +100.00%25,000 | $1.29 | $32,250 | View SEC filing | |
| 2022-11-14 | Hahn Brian M. SVP Finance, CFO | Purchase | +20,000 | +54.28%56,843 | $1.06 | $21,200 | View SEC filing | |
| 2022-11-14 | Magnani John L. SVP of Research, CSO | Purchase | +45,045 | +14.03%366,078 | $1.17 | $52,703 | View SEC filing |
1-25 of 63